Protalix BioTherapeutics, Inc. (PLX)

Protalix BioTherapeutics Revenue

Protalix BioTherapeutics had revenue of $17.96M in the quarter ending September 30, 2024, with 73.60% growth. This brings the company's revenue in the last twelve months to $45.67M, down -28.22% year-over-year. In the year 2023, Protalix BioTherapeutics had annual revenue of $65.49M with 37.48% growth.

• Revenue (ttm): $45.67M
• Revenue Growth: -28.22%
• P/S Ratio: 3.59
• Revenue / Employee: $219,553
• Employees: 208
• Market Cap: 159.78M

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	65.49M	17.86M	37.48%
Dec 31, 2022	47.64M	9.29M	24.22%
Dec 31, 2021	38.35M	-24.55M	-39.03%
Dec 31, 2020	62.90M	8.21M	15.00%
Dec 31, 2019	54.69M	20.45M	59.73%

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.